Raiffeisen Bank International AG Has $23.03 Million Position in Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Raiffeisen Bank International AG has increased its holdings in Bristol Myers Squibb by 4.4%, acquiring an additional 16,059 shares to total 383,299 shares, valued at approximately $23 million.
• Bristol Myers Squibb reported earnings of $1.46 per share, exceeding analysts' expectations of $1.07, and achieved revenues of $12.27 billion for the quarter.
• The company declared a quarterly dividend of $0.62, resulting in an annualized yield of 5.6%, with a payout ratio currently at 100%.

Raiffeisen Bank International AG boosted its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 383,299 shares of the biopharmaceutical company's stock after buying an additional 16,059 shares during the quarter. Raiffeisen Bank International AG's holdings in Bristol Myers Squibb were worth $23,032,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Heritage Trust Co increased its position in shares of Bristol Myers Squibb by 17.9% during the 1st quarter. Heritage Trust Co now owns 25,287 shares of the biopharmaceutical company's stock worth $1,542,000 after purchasing an additional 3,833 shares during the last quarter. Avalon Trust Co boosted its stake in shares of Bristol Myers Squibb by 379.3% during the 1st quarter. Avalon Trust Co now owns 2,497 shares of the biopharmaceutical company's stock worth $152,000 after acquiring an additional 1,976 shares during the period. Delta Financial Group Inc. boosted its stake in shares of Bristol Myers Squibb by 6.3% during the 1st quarter. Delta Financial Group Inc. now owns 46,807 shares of the biopharmaceutical company's stock worth $2,858,000 after acquiring an additional 2,779 shares during the period. Scotia Capital Inc. boosted its stake in shares of Bristol Myers Squibb by 6.8% during the 1st quarter. Scotia Capital Inc. now owns 366,127 shares of the biopharmaceutical company's stock worth $22,330,000 after acquiring an additional 23,242 shares during the period. Finally, Cheviot Value Management LLC bought a new position in shares of Bristol Myers Squibb during the 1st quarter worth approximately $252,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock traded down $0.01 during trading on Tuesday, reaching $45.39. 2,538,323 shares of the company's stock were exchanged, compared to its average volume of 13,487,302. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The company has a market cap of $92.37 billion, a P/E ratio of 18.22, a PEG ratio of 2.33 and a beta of 0.36. The firm's 50-day moving average price is $47.48 and its 200 day moving average price is $52.15.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The company had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter in the previous year, the firm earned $2.07 EPS. Bristol Myers Squibb's revenue was up .6% on a year-over-year basis. As a group, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.5%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Analyst Ratings Changes

Several brokerages have recently commented on BMY. Piper Sandler began coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price for the company. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday. UBS Group reduced their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Finally, William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.